Jason S. Lewis

Copper-64-pyruvaldehyde-bis(N(4)-methylthiosemicarbazone) for the prevention of tumor growth at wound sites following laparoscopic surgery: monitoring therapy response with microPET and magnetic resonance imaging.

Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships.

DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy.

Small animal imaging. current technology and perspectives for oncological imaging.

Delineation of hypoxia in canine myocardium using PET and copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone).

Molecular imaging: the application of small animal positron emission tomography.

Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report.

In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM.

Intra-tumoral distribution of (64)Cu-ATSM: a comparison study with FDG.

[Tc(CO)(3)](+) chemistry: a promising new concept for SPECT? Against.

Preparation of 66Ga- and 68Ga-labeled Ga(III)-deferoxamine-folate as potential folate-receptor-targeted PET radiopharmaceuticals.

Enhancing targeted radiotherapy by copper(II)diacetyl- bis(N4-methylthiosemicarbazone) using 2-deoxy-D-glucose.

Basic characterization of 64Cu-ATSM as a radiotherapy agent.

Investigation into 64Cu-labeled Bis(selenosemicarbazone) and Bis(thiosemicarbazone) complexes as hypoxia imaging agents.

Dosimetry of 60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET.

Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.

Imaging of melanoma using 64Cu- and 86Y-DOTA-ReCCMSH(Arg11), a cyclized peptide analogue of alpha-MSH.

Positron-emitting isotopes produced on biomedical cyclotrons.

A tat fusion protein-based tumor vaccine for breast cancer.

Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM.

Identification of a novel prostate tumor target, mindin/RG-1, for antibody-based radiotherapy of prostate cancer.

Measurement of input functions in rodents: challenges and solutions.

Preparation of high specific activity (86)Y using a small biomedical cyclotron.

Minimally invasive method of determining blood input function from PET images in rodents.

Assessment of myocardial blood flow using 15O-water and 1-11C-acetate in rats with small-animal PET.

In vivo skeletal imaging of 18F-fluoride with positron emission tomography reveals damage- and time-dependent responses to fatigue loading in the rat ulna.

Three-dimensional maximum a posteriori (MAP) imaging with radiopharmaceuticals labeled with three Cu radionuclides.

Assessment of myocardial metabolism in diabetic rats using small-animal PET: a feasibility study.

Validation of a novel CHX-A'' derivative suitable for peptide conjugation: small animal PET/CT imaging using yttrium-86-CHX-A''-octreotide.

Imaging oxygenation of human tumours.

Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy.

64Cu-azabicyclo[3.2.2]nonane thiosemicarbazone complexes: radiopharmaceuticals for PET of topoisomerase II expression in tumors.

Synthesis and biologic evaluation of 64Cu-labeled rhenium-cyclized alpha-MSH peptide analog using a cross-bridged cyclam chelator.

In vivo imaging in a murine model of glioblastoma.

Molecular imaging of gastrin-releasing peptide receptor-positive tumors in mice using 64Cu- and 86Y-DOTA-(Pro1,Tyr4)-bombesin(1-14).

Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia.

Gallium-68-labeled DOTA-rhenium-cyclized alpha-melanocyte-stimulating hormone analog for imaging of malignant melanoma.

Synthesis, in vitro and in vivo characterization of (64)Cu(I) complexes derived from hydrophilic tris(hydroxymethyl)phosphane and 1,3,5-triaza-7-phosphaadamantane ligands.

Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone).

1-11C-acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer.

Examining the relationship between Cu-ATSM hypoxia selectivity and fatty acid synthase expression in human prostate cancer cell lines.

In vitro and in vivo evaluation of bifunctional bisthiosemicarbazone 64Cu-complexes for the positron emission tomography imaging of hypoxia.

An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix.

Radiometal-labeled somatostatin analogs for applications in cancer imaging and therapy.

Evaluation of a bromine-76-labeled progestin 16alpha,17alpha-dioxolane for breast tumor imaging and radiotherapy: in vivo biodistribution and metabolic stability studies.

Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.

Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study.

Synthesis and characterization of the copper(II) complexes of new N2S2-donor macrocyclic ligands: synthesis and in vivo evaluation of the (64)Cu complexes.

In vivo biodistribution, PET imaging, and tumor accumulation of 86Y- and 111In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice.

Bromination from the macroscopic level to the tracer radiochemical level: (76)Br radiolabeling of aromatic compounds via electrophilic substitution.

(64)Cu-labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity.

Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET.

A novel technology for the imaging of acidic prostate tumors by positron emission tomography.

Melanoma imaging using (111)In-, (86)Y- and (68)Ga-labeled CHX-A''-Re(Arg11)CCMSH.

Standardized methods for the production of high specific-activity zirconium-89.

Nitroimidazole conjugates of bis(thiosemicarbazonato)64Cu(II) - Potential combination agents for the PET imaging of hypoxia.

Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab.

Unconventional nuclides for radiopharmaceuticals.

Clickable bifunctional radiometal chelates for peptide labeling.

Improved synthesis of 2'-deoxy-2'-[18F]-fluoro-1-beta-D-arabinofuranosyl-5-iodouracil ([18F]-FIAU).

Cerenkov luminescence imaging of medical isotopes.

89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.

Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes.

Role of metalation in the topoisomerase IIα inhibition and antiproliferation activity of a series of α-heterocyclic-N4-substituted thiosemicarbazones and their Cu(II) complexes.

Magnitude of enhanced permeability and retention effect in tumors with different phenotypes: 89Zr-albumin as a model system.

A practical guide to the construction of radiometallated bioconjugates for positron emission tomography.

Intraoperative imaging of positron emission tomographic radiotracers using Cerenkov luminescence emissions.

The next generation of positron emission tomography radiopharmaceuticals in oncology.

The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression in cancer.

Modular strategy for the construction of radiometalated antibodies for positron emission tomography based on inverse electron demand Diels-Alder click chemistry.

Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET.

Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90.

89Zr-labeled dextran nanoparticles allow in vivo macrophage imaging.

Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen.

Efficient (18)F-labeling of large 37-amino-acid pHLIP peptide analogues and their biological evaluation.

An improved strategy for the synthesis of [¹⁸F]-labeled arabinofuranosyl nucleosides.

PET imaging with ⁸⁹Zr: from radiochemistry to the clinic.

Annotating MYC status with 89Zr-transferrin imaging.

H(2)azapa: a versatile acyclic multifunctional chelator for (67)Ga, (64)Cu, (111)In, and (177)Lu.

(89)Zr-Labeled Paramagnetic Octreotide-Liposomes for PET-MR Imaging of Cancer.

Imaging Tumor Burden in the Brain with 89Zr-Transferrin.

Antilipolytic drug boosts glucose metabolism in prostate cancer.

Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET.

The growing impact of bioorthogonal click chemistry on the development of radiopharmaceuticals.

Enzyme-mediated methodology for the site-specific radiolabeling of antibodies based on catalyst-free click chemistry.

A Pretargeted PET Imaging Strategy Based on Bioorthogonal Diels-Alder Click Chemistry.

Fatty acid synthase is a key target in multiple essential tumor functions of prostate cancer: uptake of radiolabeled acetate as a predictor of the targeted therapy outcome.

Sandmeyer reaction repurposed for the site-selective, non-oxidizing radioiodination of fully-deprotected peptides: studies on the endogenous opioid peptide α-neoendorphin.

H(4)octapa-trastuzumab: versatile acyclic chelate system for 111In and 177Lu imaging and therapy.

Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer.

Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology.

H6phospa-trastuzumab: bifunctional methylenephosphonate-based chelator with 89Zr, 111In and 177Lu.

A prospective pilot study of (89)zr-j591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy.

Synthesis and evaluation of 18F-labeled benzylguanidine analogs for targeting the human norepinephrine transporter.

(18)F-labeled-bioorthogonal liposomes for in vivo targeting.

Underscoring the influence of inorganic chemistry on nuclear imaging with radiometals.

Influence of free fatty acids on glucose uptake in prostate cancer cells.

Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG.

Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma.

Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer.

Noninvasive Imaging of PSMA in prostate tumors with (89)Zr-Labeled huJ591 engineered antibody fragments: the faster alternatives.

Understanding the pharmacological properties of a metabolic PET tracer in prostate cancer.

Building Blocks for the Construction of Bioorthogonally Reactive Peptides via Solid-Phase Peptide Synthesis.

Alternative chelator for ⁸⁹Zr radiopharmaceuticals: radiolabeling and evaluation of 3,4,3-(LI-1,2-HOPO).

In vivo imaging of GLP-1R with a targeted bimodal PET/fluorescence imaging agent.

Development of a minimal saponin vaccine adjuvant based on QS-21.

Targeting breast tumors with pH (low) insertion peptides.

A modular labeling strategy for in vivo PET and near-infrared fluorescence imaging of nanoparticle tumor targeting.

CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma.

⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.

What a difference a carbon makes: H₄octapa vs H₄C3octapa, ligands for In-111 and Lu-177 radiochemistry.

Synthesis and evaluation of (18)F-labeled ATP competitive inhibitors of topoisomerase II as probes for imaging topoisomerase II expression.

Chemoenzymatic strategy for the synthesis of site-specifically labeled immunoconjugates for multimodal PET and optical imaging.

Annotating STEAP1 regulation in prostate cancer with 89Zr immuno-PET.